NCT06131645View on ClinicalTrials.gov

IASLC Grading System as a Predictor for EGFR-TKI Therapy

CompletedOBSERVATIONAL

Enrollment

2,160

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

December 31, 2022

Study Completion Date

July 1, 2023

Conditions

Lung Cancer

Interventions

DIAGNOSTIC_TEST

IASLC grading system

A cohort of 2160 patients with invasive nonmucinous EGFR-mutant LADCs were retrospectively collected and classified according to the IASLC grading system. The role of IASLC grading system in EGFR tyrosine kinase inhibitor (TKI) therapy selection either as adjuvant or palliative therapy was investigated.

Trial Locations (1)

200032

Chaoqiang Deng, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER

NCT06131645 - IASLC Grading System as a Predictor for EGFR-TKI Therapy | Biotech Hunter | Biotech Hunter